Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$FB Topeka Capital Assigns Buy On Facebook Following Examination Of Oculus Rift Developer Headset http://www.smarteranalyst.com/2014/10/01/topeka-capital-assigns-buy-facebook-following-examination-oculus-rift-developer-headset/
$KOOL H.C. Wainwright Reiterates Buy On Cesca Therapeutics Following Release Of Its Service-Related Revenues http://www.smarteranalyst.com/2014/09/30/h-c-wainwright-reiterates-buy-cesca-therapeutics-following-release-service-related-revenues/
$EBAY Cantor Fitzgerald Maintains Buy On Ebay Following Paypal Spinoff http://www.smarteranalyst.com/2014/09/30/cantor-fitzgerald-maintains-buy-ebay-following-paypal-spinoff/
$EBAY Cantor Fitzgerald Maintains Buy On Ebay Following Paypal Spinoff http://www.smarteranalyst.com/2014/09/30/cantor-fitzgerald-maintains-buy-ebay-following-paypal-spinoff/
$APP Roth Capital Remains Positive On American Apparel Following New Executive Appointments http://www.smarteranalyst.com/2014/09/30/roth-capital-remains-positive-american-apparel-following-new-executive-appointments/
$CPRX Catalyst Pharmaceutical: Roth Capital Analyst Sees 85% Probability Of US Approval For Firdapse http://www.smarteranalyst.com/2014/09/30/catalyst-pharmaceutical-roth-capital-sees-85-probability-us-approval-firdapse/
$CPRX Catalyst Pharmaceutical: Roth Capital Analyst Sees 85% Probability Of US Approval For Firdapse http://www.smarteranalyst.com/2014/09/30/catalyst-pharmaceutical-roth-capital-sees-85-probability-us-approval-firdapse/
$GILD Deutsche Bank Reaffirms Buy On Gilead Sciences Following Discussion With Management http://www.smarteranalyst.com/2014/09/30/deutsche-bank-reaffirms-buy-gilead-sciences-following-discussion-management/
$GILD Deutsche Bank Reaffirms Buy On Gilead Sciences Following Discussion With Management http://www.smarteranalyst.com/2014/09/30/deutsche-bank-reaffirms-buy-gilead-sciences-following-discussion-management/
$KERX H.C. Wainwright Reiterates Buy On Keryx Following Initiation Of A New Phase 3 Study http://www.smarteranalyst.com/2014/09/30/h-c-wainwright-reiterates-buy-keryx-following-initiation-new-phase-3-study/
$CPRX Scarcity Value Inherent In CPRX Story Remains Underappreciated, Says H.C. Wainwright http://www.smarteranalyst.com/2014/09/30/scarcity-value-inherent-cprx-story-remains-underappreciated-says-h-c-wainwright/
$KERX Maxim Raises Keryx Price Target To $26 Following Ferric Citrate Pricing http://www.smarteranalyst.com/2014/09/30/maxim-raises-keryx-price-target-26-following-ferric-citrate-pricing/
$KERX Maxim Raises Keryx Price Target To $26 Following Ferric Citrate Pricing http://www.smarteranalyst.com/2014/09/30/maxim-raises-keryx-price-target-26-following-ferric-citrate-pricing/
$ARIA H.C. Wainwright Reiterates Buy On Ariad Following Clinical Data On AP26113 http://www.smarteranalyst.com/2014/09/30/h-c-wainwright-reiterates-buy-ariad-following-clinical-data-ap26113/
$ARIA H.C. Wainwright Reiterates Buy On Ariad Following Clinical Data On AP26113 http://www.smarteranalyst.com/2014/09/30/h-c-wainwright-reiterates-buy-ariad-following-clinical-data-ap26113/
$SGEN Seattle Genetics: Positive Ph 3 AETHERA Trial Paves Path For Significant Market Potential, Says William Blair http://www.smarteranalyst.com/2014/09/29/seattle-genetics-positive-phase-3-aethera-trial-paves-path-significant-market-potential-says-william-blair/
$GALE Roth Capital Reiterates Buy On Galena Following Release Of Special Committee Report http://www.smarteranalyst.com/2014/09/29/roth-capital-reiterates-buy-galena-following-release-special-committee-report/
$KERX Roth Capital Maintains Bullish Stance On Keryx Following Phase 3 Initiation in CKD http://www.smarteranalyst.com/2014/09/29/roth-capital-maintains-bullish-stance-keryx-following-phase-3-initiation-ckd/
$IMUC Maxim Group Maintains Buy On ImmunoCellular Following Agreement With The California Institute http://www.smarteranalyst.com/2014/09/29/maxim-group-maintains-buy-immunocellular-following-agreement-california-institute/
$ETRM Roth Capital Maintains Buy On Enteromedics Following CE Mark Expansion http://www.smarteranalyst.com/2014/09/29/roth-capital-maintains-buy-enteromedics-following-ce-mark-expansion/
$ETRM Roth Capital Maintains Buy On Enteromedics Following CE Mark Expansion http://www.smarteranalyst.com/2014/09/29/roth-capital-maintains-buy-enteromedics-following-ce-mark-expansion/
$MACK Brean Capital Reiterates Buy On Merrimack On The Back Of Pipeline Update http://www.smarteranalyst.com/2014/09/29/brean-capital-reiterates-buy-merrimack-back-pipeline-update/
$MACK Brean Capital Reiterates Buy On Merrimack On The Back Of Pipeline Update http://www.smarteranalyst.com/2014/09/29/brean-capital-reiterates-buy-merrimack-back-pipeline-update/
$RNN Roth Capital Maintained Buy On Rexahn Pharmaceuticals On FDA Orphan Designation http://www.smarteranalyst.com/2014/09/25/roth-capital-maintained-buy-rexahn-pharmaceuticals-fda-orphan-designation/
$RNN Roth Capital Maintained Buy On Rexahn Pharmaceuticals On FDA Orphan Designation http://www.smarteranalyst.com/2014/09/25/roth-capital-maintained-buy-rexahn-pharmaceuticals-fda-orphan-designation/
$TGTX Brean Capital Raises TG Therapeutics Price Target To $22 Following Licensing Of Full TGR-1202 Rights http://www.smarteranalyst.com/2014/09/25/brean-capital-raises-tg-therapeutics-price-target-to-22-following-licensing-of-full-tgr-1202-rights/
$CYTX Maxim Group Reiterated Buy On Cytori Therapeutics Following Restructuring Plans http://www.smarteranalyst.com/2014/09/25/maxim-group-reiterated-buy-cytori-therapeutics-following-restructuring-plans/
$CYTX Maxim Group Reiterated Buy On Cytori Therapeutics Following Restructuring Plans http://www.smarteranalyst.com/2014/09/25/maxim-group-reiterated-buy-cytori-therapeutics-following-restructuring-plans/
$IMUC Roth Capital Maintained Buy On ImmunoCellular As Pipeline Expands http://www.smarteranalyst.com/2014/09/25/roth-capital-maintained-buy-on-immunocellular-as-pipeline-expands/
Is It A Good Time To Accumulate InvenSense? Roth Capital Says Yes http://www.smarteranalyst.com/2014/09/24/good-time-accumulate-invensense-roth-capital-says-yes/
$INVN Is It A Good Time To Accumulate InvenSense? Roth Capital Says Yes http://www.smarteranalyst.com/2014/09/24/good-time-accumulate-invensense-roth-capital-says-yes/
$BIIB Cowen Comments On Biogen In Light Of Forward Pharma’s Patent Application On Tecfidera http://www.smarteranalyst.com/2014/09/24/cowen-comments-biogen-light-forward-pharmas-patent-application-tecfidera/
$ACOR Cowen Maintains Bullish Stance On Acorda In Light Of Civitas Acquisition; Raises PT To $65 http://www.smarteranalyst.com/2014/09/24/cowen-maintains-bullish-stance-acorda-light-civitas-acquisition-raises-pt-65/
$ACOR Cowen Maintains Bullish Stance On Acorda In Light Of Civitas Acquisition; Raises PT To $65 http://www.smarteranalyst.com/2014/09/24/cowen-maintains-bullish-stance-acorda-light-civitas-acquisition-raises-pt-65/
$MACK Cowen Reiterates Outperform On Merrimack In Light Of U.S. License Agreement With Baxter http://www.smarteranalyst.com/2014/09/24/cowen-reiterates-outperform-merrimack-light-u-s-license-agreement-baxter/
$GILD Gilead: Positive TAF Data Suggests There Will Be Life After Viread, Says Cowen; Raises PT To $125 http://www.smarteranalyst.com/2014/09/24/gilead-positive-taf-data-suggests-will-life-viread-says-cowen-raises-pt-125/
$OPK Oppenheimer Reiterates Outperform On Opko Health On The Heels Of Rayaldee Positive Top-Line Data http://www.smarteranalyst.com/2014/09/24/oppenheimer-reiterates-outperform-opko-health-heels-rayaldee-positive-top-line-data/
$OPK Oppenheimer Reiterates Outperform On Opko Health On The Heels Of Rayaldee Positive Top-Line Data http://www.smarteranalyst.com/2014/09/24/oppenheimer-reiterates-outperform-opko-health-heels-rayaldee-positive-top-line-data/
Oppenheimer Maintains Outperform On PTC Therapeutics Following New Trial Update http://www.smarteranalyst.com/2014/09/24/oppenheimer-maintains-outperform-ptc-therapeutics-following-new-trial-update/
$SBUX Oppenheimer Maintains Outperform On Starbucks Following Acquisition Of Starbucks Coffee Japan http://www.smarteranalyst.com/2014/09/24/oppenheimer-maintains-outperform-starbucks-following-acquisition-starbucks-coffee-japan/